Novartis reports dovitinib data in RCC

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the Phase II portion of an open-label Phase I/II trial of dovitinib to treat clear cell advanced or metastatic renal cell carcinoma (RCC). The oral ...